A Philis-Tsimikas1, K Astamirova2, Y Gupta3, A Haggag4, D Roula5, B A Bak6, E G Fita6, A M Nielsen6, T Demir7. 1. Scripps Whittier Diabetes Institute, San Diego, CA, USA. Electronic address: Philis-Tsimikas.Athena@scrippshealth.org. 2. Saint-Petersburg Territorial Diabetic Centre, Saint-Petersburg, Russia. 3. All India Institute of Medical Sciences, New Delhi, India. 4. Anaheim Clinical Trials, Anaheim, CA, USA. 5. Salah Boubnider University, Constantine, Algeria. 6. Novo Nordisk A/S, Søborg, Denmark. 7. Dokuz Eylül Üniversity, İzmir, Turkey.
Abstract
AIMS: To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulin glargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA1c after 26 weeks, and compare efficacy and safety between groups at W26 + W38. METHODS: A 38-week, randomised, open-label, treat-to-target (HbA1c < 7.0%) trial in adults with type 2 diabetes mellitus (on basal insulin ± oral antidiabetic drugs; HbA1c 7.0-10.0%). Randomisation (1:1): IDegAsp or IGlar U100 + IAsp. Intensification to IDegAsp twice daily (BID) was permitted at W26 + W32, or with additional IAsp injections at W26 (maximum IAsp BID) or W32 (maximum IAsp three-times daily). RESULTS: For W0-W26, mean percentage-change (standard deviation) HbA1c was: IDegAsp, -1.1 (0.9); IGlar U100 + IAsp, -1.1 (0.8); estimated treatment difference: 0.07% (95% confidence interval [CI]: -0.06; 0.21) confirmed non-inferiority. At W26 and W38, target HbA1c achievement, and mean fasting and postprandial glucose were similar across groups. At W38, more subjects achieved target HbA1c without hypoglycaemia with IDegAsp (22.5%) than with IGlar U100 + IAsp (21.1%), with significantly fewer nocturnal episodes (W0-W38, estimated rate ratio: 0.61 [95% CI: 0.40; 0.93]). Safety profiles were similar across treatment groups throughout. CONCLUSIONS: IDegAsp OD/BID are effective treatment intensification options versus multiple injection basal-bolus therapies, achieving similar glycaemic control, with significantly less nocturnal hypoglycaemia.
RCT Entities:
AIMS: To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulinglargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA1c after 26 weeks, and compare efficacy and safety between groups at W26 + W38. METHODS: A 38-week, randomised, open-label, treat-to-target (HbA1c < 7.0%) trial in adults with type 2 diabetes mellitus (on basal insulin ± oral antidiabetic drugs; HbA1c 7.0-10.0%). Randomisation (1:1): IDegAsp or IGlar U100 + IAsp. Intensification to IDegAsp twice daily (BID) was permitted at W26 + W32, or with additional IAsp injections at W26 (maximum IAsp BID) or W32 (maximum IAsp three-times daily). RESULTS: For W0-W26, mean percentage-change (standard deviation) HbA1c was: IDegAsp, -1.1 (0.9); IGlar U100 + IAsp, -1.1 (0.8); estimated treatment difference: 0.07% (95% confidence interval [CI]: -0.06; 0.21) confirmed non-inferiority. At W26 and W38, target HbA1c achievement, and mean fasting and postprandial glucose were similar across groups. At W38, more subjects achieved target HbA1c without hypoglycaemia with IDegAsp (22.5%) than with IGlar U100 + IAsp (21.1%), with significantly fewer nocturnal episodes (W0-W38, estimated rate ratio: 0.61 [95% CI: 0.40; 0.93]). Safety profiles were similar across treatment groups throughout. CONCLUSIONS: IDegAsp OD/BID are effective treatment intensification options versus multiple injection basal-bolus therapies, achieving similar glycaemic control, with significantly less nocturnal hypoglycaemia.
Authors: Bipin Sethi; A G Unnikrishnan; Vageesh Ayyar; P K Jabbar; K K Ganguly; Sudhir Bhandari; Ashu Rastogi; Rajarshi Mukherjee; Vivek Sundaram; Adlyne R Asirvatham Journal: Diabetes Ther Date: 2022-06-30 Impact factor: 3.595
Authors: Philip D Home; Roopa Mehta; Khadija A S Hafidh; Olesya Y Gurova; Agustina Alvarez; Paul Serafini; Mir-Masoud Pourrahmat Journal: Diabetes Obes Metab Date: 2021-08-31 Impact factor: 6.408
Authors: Sarah J Glastras; Neale Cohen; Thomas Dover; Gary Kilov; Richard J MacIsaac; Margaret McGill; Greg R Fulcher Journal: J Clin Med Date: 2020-04-11 Impact factor: 4.241